Study Hall Sample Clauses

Study Hall. 1. Where a school uses study hall to cover teacher absence, a teacher assigned to a study hall period shall not be required to supervise more than 58 students in a period.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Study Hall. Study hall classes shall not exceed fifty-five (55) students.
Sample 1Sample 2Sample 3
Study Hall. There will be a Study Hall offered for student use. Study Hall is a revocable privilege, not a right. Students are required to come prepared for study hall just as if it were a class. Parents are required to ensure that their children come prepared to use study hall for its intended purpose. Students of any age who are capable of sitting still and working independently for the duration of the class period are welcome to sit in Study Hall. Students who are not able to work independently are not permitted in the Study Hall and are encouraged to work under their parent’s direction. Students may not spend more than two consecutive class periods in Study Hall without the prior consent of the Director. Attendance will be taken by an adult monitor who will preside over each Study Hall. HTS administration reserves the right to ask parents to pick up their student from Study Hall if the student does not demonstrate the ability to work quietly and independently in Study Hall. With the exception of chess (played according to “silent rule”), no games or hand-held electronic games are permitted in Study Hall. Cell phones must be put on silent mode AND used in the office for emergency purposes only. Laptops may be used after returning a parent- and student-signed permission slip for school work only. A limited number of electrical outlets are available. MP3 players/iPods may only be used in Study Hall by students who have a parent-signed permission form on file. The intent of this option is to allow students to use audio books, foreign language audio, and for students whose study is enhanced by the use of classical music. The content of the audio device is the responsibility of the parent and will not be policed by the study hall monitor or HTS staff. Use of players without a signed permission form, and the sharing of headphones or a player with others is not allowed and will be reason for confiscation in or out of Study Hall. We recognize that internet access may be needed by high school students while they are in Study Hall. Any student needing to access the internet for research or to submit a paper must have a Student Network Use Agreement signed by a parent and the student in advance. Since Bible classes meet during the first class of the day on Tuesdays, there will be no study hall available until 9:40am. Parents should, therefore, plan to either enroll their children in a Bible class or not drop them off until their first class of the day. Food and Lunch No snack...
Sample 1
Study Hall. 50 students per adult with no more than 125 total.
Sample 1
Study Hall. The study period is a rostered class. Students report to the auditorium and sit every other seat, every other row. Any student not in her seat at the bell is late. The following procedures apply for all study periods, first through eighth periods: • Silence is to be observed in study hall. • Students will be assigned places every other seat, every other row; assigned seats can be changed only by the moderator. • Students may leave study hall only with permission of the moderator. • Students who must make up tests during study period must present a note from the classroom teacher requesting that they be excused. • If a student is going to report to the library or the computer lab during study she must do so by the second bell. The sign-in sheet validates the absence from study and serves as permission to use the library or computer lab.
Sample 1
Study Hall. The study period is a rostered class. Students report to the auditorium and sit according to the instructions of the moderator.. Any student not in her seat at the bell is late. The following procedures apply for all study periods, first through eighth periods: • Silence is to be observed in study hall. • Students will be assigned seats; assigned seats can be changed only by the moderator. • Students may leave study hall only with permission of the moderator. • If a student is going to make up a test during Study Hall, she must first report to Study Hall for attendance, present a note from the subject teachers, and go directly to the classroom with the permission of the moderator. • If a student is going to report to the library or the computer lab during study hall , she must first report to Study Hall for attendance and then sign out with the permission of the moderator. She must also sign in when she reaches the library or computer lab. If a student fails to follow these procedures she will be considered cutting class and appropriate disciplinary action will be taken.
Sample 1
Study Hall. Study Hall assignments shall be made to teachers on an equitable basis not to exceed ninety (90) hours per year. Division chairpersons, association president, counselors, student council advisor(s), social worker, psychologist, school nurse, AP teachers, and shall not normally serve in Study Hall/Hall Supervision. The above may be used as Study Hall supervisors in emergencies to fill hours of the day when no teachers are available or to equalize the Study Hall assignments. Preference for assignments shall be solicited and made on the basis of seniority. Teachers with seniority who have not received their preference may request special administrative review.
Sample 1
AutoNDA by SimpleDocs
Study Hall. Scheduled study halls shall be taught by certified teachers.
Sample 1
Study Hall a. Team study hall will be held every Wednesday from 3:15-4:15PM. All students must text Coach Xxxxx a screen capture/picture of their standing grades in all subjects the Monday before each study hall. This will allow coaches to check on progress and assist with any gaps in assignments or provide extra assistance in areas that need it.
Sample 1

Related to Study Hall

  • Study Design This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.